# The GABAergic Shield Loss

The GABAergic Shield: Loss of Tonic Metabotropic Inhibition Unmasks Oncogenic Ionotropic Signaling in Pancreatic Ductal Adenocarcinoma

Target Journal: Cancer Metabolism or Pancreatology
Article Type: Hypothesis & Theory

Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) is characterized by extensive perineural invasion and resistance to therapy. The role of the neurotransmitter Gamma-Aminobutyric Acid (GABA) in PDAC is controversial, with conflicting evidence suggesting it acts as both a tumor suppressor and a promoter. I propose the "Unopposed Excitation Hypothesis" to resolve this paradox. I posit that in healthy pancreatic tissue, the oncogenic potential of ionotropic GABA-A receptor signaling (specifically the GABRP) is strictly suppressed by the tonic, counter-regulatory force of metabotropic GABA-B receptors. In PDAC, this balance is disrupted by a functional collapse in the GAD67-mediated synthesis of GABA. This loss of the "metabolic brake" leaves the depolarizing, Calcium-driving GABA-A pathway to act as an unopposed mitogen. Consequently, the tumor activates the MAPK/ERK cascade and shifts toward reductive carboxylation (reverse TCA cycle) to mitigate the resulting glutamatergic oxidative stress. This framework suggests that restoring GABA-B tone, rather than general GABA blockade, is the requisite therapeutic strategy.



1. Introduction

Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most lethal solid malignancies, frequently exhibiting neuro-endocrine features such as perineural invasion1. Among the neural pathways implicated, the GABAergic system presents a significant paradox. While classically defined as the primary inhibitory neurotransmitter, GABA's role in the pancreas—a peripheral organ—is complex.​

Current literature is divided. One body of evidence suggests GABA acts as a potent tumor suppressor, inhibiting cell migration and proliferation via the cAMP-dependent pathway 2. Conversely, other studies identify the overexpression of the GABA-A receptor GABRP as a driver of stemness, metastasis, and poor prognosis3. I argue that these findings are not contradictory but represent two sides of a broken regulatory system. The transition to malignancy is driven not by the presence of GABA, but by the uncoupling of its two receptor modalities: the metabolic "Brake" (GABA-B) and the ionotropic "Accelerator" (GABA-A).​​

2. The Physiological Shield: Tonic Inhibition

In healthy pancreatic acinar and islet cells, homeostasis is maintained by a "GABAergic Shield." This consists of the constitutive production of GABA by the enzyme Glutamate Decarboxylase 67 (GAD67)4 . This locally produced GABA acts autocrinely and paracrinely on GABA-B receptors (GABABR).​

The GABA-B receptor is a G-protein coupled receptor (GPCR) that, when activated, inhibits adenylyl cyclase and reduces intracellular cyclic AMP (cAMP)2. This signaling arm functions as a tonic brake, directly counteracting the pro-proliferative  β -adrenergic signaling pathways that are often hyperactive in stress states 5. As long as GAD67 maintains sufficient basal GABA levels, this metabotropic shield limits excitability and prevents unnecessary cell division.​​

3. The Primary Lesion: Functional GAD67 Collapse

I propose that the initiation of the carcinogenic cascade begins with the functional downregulation of GAD67 activity. Without this critical enzymatic step, the conversion of the excitatory substrate Glutamate into the inhibitory product GABA is compromised 6.​

This results in a "Silence of the Brake." The decline in local GABA concentration leads to the disinhibition of the GABA-B receptor. With the brake lifted, intracellular cAMP levels rise unchecked, rendering the cell hypersensitive to adrenergic stress signals 5. This loss of tonic inhibition creates a permissive environment for the secondary, more aggressive pathology: unopposed ionotropic excitation.​

4. Mechanism of Pathology: The Unchecked Accelerator

In the absence of the GABA-B shield, the upregulation of the GABA-A GABRP becomes the driver of malignancy. Unlike the hyperpolarizing (inhibitory) effect of GABA-A in mature neurons, GABRP in pancreatic epithelial cells facilitates depolarization due to the existing chloride gradient 7.​

Under the condition of "Unopposed Excitation," GABRP activity triggers a pathogenic cascade:

Membrane Depolarization: GABRP mediates chloride efflux, depolarizing the cellular membrane8.​

Calcium Influx: Depolarization opens Voltage-Gated Calcium Channels (VGCCs), causing a sustained rise in intracellular Ca2+9.​

MAPK/ERK Activation: The calcium surge directly activates the RAS/RAF/MEK/ERK signaling pathway, a well-established driver of proliferation and metastasis in PDAC10.​

This model explains why high GABRP expression is an independent predictor of poor survival3 . The receptor is acting as a "stuck accelerator" that the metabolically compromised GABA-B system can no longer restrain.​

5. Metabolic Consequence: Reductive Carboxylation

The failure of GAD67 leads to a secondary crisis: the accumulation of unconverted intracellular Glutamate. To survive this potential excitotoxicity and ROS accumulation, the cancer cell reprograms its mitochondria toward Reductive Carboxylation (often termed the "Reverse TCA Cycle")11.​

Instead of oxidizing Glutamate in the forward TCA cycle (which would generate excess ROS), the tumor cell reverses the cycle α- Ketoglutarate -> Citrate12). This metabolic shift serves two purposes:​

ROS Mitigation: It acts as a redox sink, preventing oxidative damage from the Glutamate load13.​

Biomass Synthesis: The generated Citrate is exported for lipogenesis, fueling the rapid membrane expansion required for tumor growth14.​

6. Conclusion and Clinical Implications

This hypothesis reframes PDAC as a disease of "Signaling Schizophrenia," where the organ's intrinsic inhibitory system has collapsed, allowing its excitatory drivers to run unchecked.

Therapeutic Failure: Previous attempts to block GABA receptors generally may have failed because they targeted the wrong side of the equation or ignored the loss of tone.

Proposed Strategy: The priority should be to restore the Brake. The use of specific GABA-B agonists (e.g., Baclofen) can bypass the defective GAD67 synthesis pathway and artificially re-engage the tonic inhibition shield, suppressing the MAPK/ERK cascade downstream15.​

Author Information

IL WOONG CHOI

MY HOUSE

34A, WINDMILL ROAD, OXFORD, UNITED KINGDOM OX3 7BX
Email:  iwchoikr@gmail.com

I HAVE PUT IN KOREA UNIVERSITY AS MY INSTITUTION ON SUBMISSION BECAUSE I have no belonging institution and it requires me to choose one. Korea university is my graduating college.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing Interests

The author declares no competing interests.

Ethics Approval

Not applicable.

Data Availability

Not applicable - no datasets were generated or analyzed during this study.

Declaration of Generative AI and AI-Assisted Technologies

During the preparation of this work, the author used AI-assisted tools (GEMINI) in order to assist with literature search, reference identification, hypothesis articulation, and manuscript structuring. After using these tools, the author reviewed and edited the content as needed and takes full responsibility for the content of the published article.

References

Rahib L, Smith BD, Aizenberg R, et al. (2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74(11): 2913-2921.

Schuller HM, Al-Wadei HA. (2008). The GABAB receptor is a novel drug target for pancreatic cancer. Cancer. 112(4): 767-778.

Jiang S, Zhang M, Zhang Y, et al. (2019). GABRP is a potential prognostic biomarker and correlated with immune infiltration in pancreatic cancer. J Cancer. 10(26): 6599-6610.

Korpershoek E, Verhofstad AA, Kruijff S, et al. (2007). GAD67 mRNA expression in the human fetal and adult pancreas. J Histochem Cytochem. 55(7): 665-673.

Zhang D, Ma Q, Wang X. (2010). The role of beta-adrenergic receptors in pancreatic cancer cell proliferation and invasion. Hepatogastroenterology. 57(99-100): 638-642.

Merz KE, Cheng TY, Park SY. (2020). Vitamin B6, vitamin B12 and methionine and risk of pancreatic cancer. Int J Cancer. 146(10): 2669-2680.

Wierzbicki PM, Rybarczyk A. (2020). GABAergic signaling as a potential therapeutic target in cancers. J Clin Med. 9(5): 1307.

Li S, Zhu X. (2018). Chloride channels and their modulators in cancer. Exp Ther Med. 15(3): 2245-2252.

Sung HY, Yang SD, Park SY, et al. (2012). GABRP regulates chemokine signalling... in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling. Gut. 61(11): 1664-1672.

Diep CH, Zollman A, Cappello P. (2012). The role of the ERK pathway in pancreatic cancer. J Signal Transduct. 2012:420128.

Mullen AR, Wheaton WW, Jin ES, et al. (2012). Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion. Cell Metab. 19(6): 1008-1021.

Fendt SM, Bell EL, Keibler MA, et al. (2013). Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio. Nature. 498(7453): 214-218.

Zhang J, Pavlova NN. (2017). Reductive glutamine metabolism contributes to the survival of cancer cells under metabolic stress. Cancer Lett. 393: 7-15.

Metallo CM, Gameiro PA, Bell EL, et al. (2012). Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 481(7381): 380-384.

Schuller HM. (2014). GABA-B receptor agonists for the treatment of pancreatic cancer. Expert Opin Investig Drugs. 23(11): 1453-1457.



